14-day Premium Trial Subscription Sign Up For FreeGet Free

Catalyst Pharmaceuticals Stock Forecast NASDAQ:CPRX

$5.54 (-2.64%)

Volume: 2M

Closed: Jan 21, 2022

Hollow Logo Score: -3.280

Catalyst Pharmaceuticals Stock Forecast

$5.54 (-2.64%)

Volume: 2M

Closed: Jan 21, 2022

Score Hollow Logo -3.280

Catalyst Pharmaceuticals Company Profile

355 Alhambra Circle

Coral Gables FL 33134



Industry: Biotechnology

Sector: Healthcare

Catalyst Pharmaceuticals


Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies for people with rare debilitating diseases. Its lead product candidate is Firdapse, a proprietary form of amifampridine phosphate, which completed Phase III clinical trial for the treatment of patients with Lambert-Eaton Myasthenic syndrome; and is in small blinded clinical trial to treat Congenital Myasthenic syndromes, as well as is in Phase II/III clinical trial for the treatment of MuSK-antibody positive myasthenia gravis. The company also develops CPP-115, a GABA aminotransferase inhibitor that is in Phase Ib clinical trial for the treatment of epilepsy and other neurological indications, such as complex partial seizures and Tourette’s disorder; and CPP-109 to treat Tourette’s disorder. It has a strategic collaboration with BioMarin Pharmaceutical Inc. for the development of Firdapse. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE